Frank Sciurba
Specialist
3601 5th Ave, 4th Floor Falk, Comprehensive Lung Center
Pittsburgh, PA 15213
- Medicare participating
At a glance
- Medical school
- University of Chicago, Pritzker School of Medicine (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 53
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1982Medical school: University of Chicago, Pritzker School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
PA license MD031905E
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UPMC Presbyterian Shadyside Pittsburgh, PA
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- UPMC PAssavant Pittsburgh, PA
- UPMC Mercy Pittsburgh, PA
Medical groups
- University of Pittsburgh Physicians (4,236 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 53
- Services billed
- 87
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 22 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Pittsburgh, PA | 163 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Pittsburgh, PA | 65 |
| Prednisone Other prescribers in Pittsburgh, PA | 63 |
| Azithromycin Other prescribers in Pittsburgh, PA | 52 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Pittsburgh, PA | 38 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Pittsburgh, PA | 37 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Pittsburgh, PA | 28 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Pittsburgh, PA | 26 |
| Ciprofloxacin Hcl Other prescribers in Pittsburgh, PA | 24 |
| Prolastin C (alpha-1-proteinase inhibitor) | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 41 payments worth $36,552 in total to this clinician.
| Genzyme Corporation | $14,245 |
|---|---|
| GlaxoSmithKline, LLC. | $8,957 |
| Genentech USA, Inc. | $8,164 |
| Pulmonx Corporation | $2,917 |
| AstraZeneca Pharmaceuticals LP | $1,746 |
| AstraZeneca UK Limited | $269 |
| Verona Pharma, Inc. | $108 |
| United Therapeutics Corporation | $72.57 |
| Consulting Fee | $32,615 |
|---|---|
| Food and Beverage | $2,228 |
| Travel and Lodging | $1,709 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Aug 23, 2025 | Consulting Fee | $7,535 |
| Genzyme Corporation Jun 6, 2025 | Consulting Fee | $6,000 |
| Genzyme Corporation Mar 1, 2025 | Consulting Fee | $5,925 |
| GlaxoSmithKline, LLC. Jun 16, 2025 | Consulting Fee NUCALA · IMMUNOLOGY | $2,600 |
| GlaxoSmithKline, LLC. Apr 15, 2025 | Consulting Fee | $2,600 |
| Pulmonx Corporation Nov 24, 2025 | Consulting Fee PULMONX CHARTIS TABLET CONSOLE; ZEPHYR DELIVERY CATHETER; CHARTIS CATHETER · PULMONOLOGY | $2,500 |
| GlaxoSmithKline, LLC. Jun 3, 2025 | Consulting Fee | $1,950 |
| GlaxoSmithKline, LLC. Oct 14, 2025 | Consulting Fee | $1,625 |
| AstraZeneca Pharmaceuticals LP Oct 21, 2025 | Consulting Fee FASENRA · Respiratory | $1,611 |
| Genzyme Corporation Mar 1, 2025 | Travel and Lodging travel to Cambridge, MA, MA · in-kind | $790 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca UK Limited Dec 17, 2025 | Consulting Fee | $269 |
| Pulmonx Corporation Nov 24, 2025 | Consulting Fee PULMONX CHARTIS TABLET CONSOLE; ZEPHYR DELIVERY CATHETER; CHARTIS CATHETER · PULMONOLOGY | $2,500 |
| AstraZeneca Pharmaceuticals LP Oct 21, 2025 | Consulting Fee FASENRA · Respiratory | $1,611 |
| GlaxoSmithKline, LLC. Oct 14, 2025 | Consulting Fee | $1,625 |
| Genentech USA, Inc. Aug 23, 2025 | Consulting Fee | $7,535 |
| Genentech USA, Inc. Aug 23, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $149 |
| Genentech USA, Inc. Aug 23, 2025 | Travel and Lodging travel to Rosemont, IL | $40.00 |
| GlaxoSmithKline, LLC. Jun 16, 2025 | Consulting Fee NUCALA · IMMUNOLOGY | $2,600 |
| Genzyme Corporation Jun 6, 2025 | Consulting Fee | $6,000 |
| Genzyme Corporation Jun 6, 2025 | Travel and Lodging travel to Rosemont, IL | $222 |
| Genzyme Corporation Jun 6, 2025 | Travel and Lodging travel to Rosemont, IL · in-kind | $206 |
| GlaxoSmithKline, LLC. Jun 3, 2025 | Consulting Fee | $1,950 |
| GlaxoSmithKline, LLC. Apr 15, 2025 | Consulting Fee | $2,600 |
| Genzyme Corporation Mar 1, 2025 | Consulting Fee | $5,925 |
| Genzyme Corporation Mar 1, 2025 | Travel and Lodging travel to Cambridge, MA, MA · in-kind | $790 |
| Genzyme Corporation Mar 1, 2025 | Travel and Lodging travel to Cambridge, MA, MA · in-kind | $173 |
| Genzyme Corporation Mar 1, 2025 | Travel and Lodging travel to Cambridge, MA, MA · in-kind | $130 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $209,140 in research payments for these studies, mostly to the institutions running them.
- A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic O…
AstraZeneca Pharmaceuticals LP - Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
Verona Pharma, Inc. - CS006 RHEOX PIVOTAL
Galvanize Therapeutics, Inc - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chron…
AstraZeneca Pharmaceuticals LP - A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obs…
AstraZeneca Pharmaceuticals LP - Zephyr Valve Registry
Pulmonx Corporation - A Phase II Randomized Double-blind Placebo controlled Study to Assess the Efficacy Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchi…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.